Stemness Inhibitor Tested in Rare Hematologic Cancer

10:02 EDT 17 May 2018 | OncLive

SL-401, a novel therapy that targets a cancer stemness pathway, is being investigated in patients with blastic plasmacytoid dendritic cell neoplasm in a phase I/II trial.

Original Article: Stemness Inhibitor Tested in Rare Hematologic Cancer


More From BioPortfolio on "Stemness Inhibitor Tested in Rare Hematologic Cancer"

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...